Brought to you by:
Endovascular CFA treatment associated with increased rate of long-term CFA-specific reintervention, study finds
A recent study suggests that endovascular treatment of the common femoral artery (CFA) is associated with an increased rate of long-term CFA-specific reintervention, regardless of indication. Nicholas Wells, MA, a medical student at Yale School of Medicine in New Haven,…
Aspirex achieves 78% two-year primary patency rate in P-MAX postmarket observational study
At the Leipzig Interventional Course (LINC) 2024 (28–31 May, Leipzig, Germany), Michael Lichtenberg (Arnsberg Vascular Clinic, Arnsberg, Germany) shared for the first time a 24-month update from the P-MAX study of the Aspirex (BD) endovascular thrombectomy system in the treatment…
Studies highlight need for tailored treatment options for women with peripheral arterial disease
New clinical results highlight the need for inclusive approaches and comprehensive examinations of treatment options for peripheral arterial disease (PAD), including endovascular therapy and revascularisation. The data were presented recently at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024…
Frank J. Veith joins ViTAA Medical Solutions’ board of directors
ViTAA Medical Solutions has announced the appointment of Frank J Veith, MD, professor of surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio, and New York University Medical Center in New York…
Endospan releases early TRIOMPHE IDE study results at Society of Thoracic Surgeons annual meeting
Endospan shared 30-day results from the first 22 patients enrolled in the TRIOMPHE investigational device exemption (IDE) study in a late-breaking presentation at the 60th annual meeting of the Society of Thoracic Surgeons (27–29 January, San Antonio, USA). TRIOMPHE is…
Thrombolex announces new insights from the RESCUE trial with the Bashir endovascular catheter
Thrombolex has announced never-before-reported major reductions in obstruction in all of the segmental pulmonary arteries (PA), based on independent core lab data analysis of 107 patients from 18 sites in the USA, with acute intermediate-risk pulmonary embolism (PE), using the…
Nectero Medical receives FDA clearance of IND application to initiate Phase II/III clinical trial of Nectero EAST system
Nectero Medical today announced that the US Food and Drug Administration (FDA) has granted investigational new drug (IND) clearance for the company to initiate a prospective, multicentre, randomised clinical trial (the stAAAble study) to evaluate the safety and efficacy of…
The top 10 most popular Vascular Specialist stories of June 2023
Last month, Vascular Specialist garnered readers’ attention with an array of commentary on the BEST-CLI and BASIL-2 trials; the medical editor’s interview with vascular surgery’s ‘living legend’ Frank J. Veith, MD; the news of the death of Past SVS President…
Base revascularization strategy on effectiveness in restoring adequate and durable limb perfusion, BEST-CLI subanalysis advises
The results of a subanalysis of the BEST-CLI trial found that patients with chronic limb-threatening ischemia (CLTI) who were deemed suitable for open lower-extremity bypass surgery “have similar periprocedural complications following either open or endovascular revascularization.” The finding led researchers…
Global perspectives take center stage in second annual WFVS session at VAM
“The intellectual exchange of information and a better understanding of unique global perspectives has brought the leading societies closer,” Palma Shaw, MD, MBA, secretary general of the World Federation of Vascular Societies (WFVS) says of the success of this international…